Cargando…

mRNA trans-splicing dual AAV vectors for (epi)genome editing and gene therapy

Large genes including several CRISPR-Cas modules like gene activators (CRISPRa) require dual adeno-associated viral (AAV) vectors for an efficient in vivo delivery and expression. Current dual AAV vector approaches have important limitations, e.g., low reconstitution efficiency, production of alien...

Descripción completa

Detalles Bibliográficos
Autores principales: Riedmayr, Lisa Maria, Hinrichsmeyer, Klara Sonnie, Thalhammer, Stefan Bernhard, Mittas, David Manuel, Karguth, Nina, Otify, Dina Yehia, Böhm, Sybille, Weber, Valentin Johannes, Bartoschek, Michael David, Splith, Victoria, Brümmer, Manuela, Ferreira, Raphael, Boon, Nanda, Wögenstein, Gabriele Maria, Grimm, Christian, Wijnholds, Jan, Mehlfeld, Verena, Michalakis, Stylianos, Fenske, Stefanie, Biel, Martin, Becirovic, Elvir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10584818/
https://www.ncbi.nlm.nih.gov/pubmed/37852949
http://dx.doi.org/10.1038/s41467-023-42386-0
_version_ 1785122818448424960
author Riedmayr, Lisa Maria
Hinrichsmeyer, Klara Sonnie
Thalhammer, Stefan Bernhard
Mittas, David Manuel
Karguth, Nina
Otify, Dina Yehia
Böhm, Sybille
Weber, Valentin Johannes
Bartoschek, Michael David
Splith, Victoria
Brümmer, Manuela
Ferreira, Raphael
Boon, Nanda
Wögenstein, Gabriele Maria
Grimm, Christian
Wijnholds, Jan
Mehlfeld, Verena
Michalakis, Stylianos
Fenske, Stefanie
Biel, Martin
Becirovic, Elvir
author_facet Riedmayr, Lisa Maria
Hinrichsmeyer, Klara Sonnie
Thalhammer, Stefan Bernhard
Mittas, David Manuel
Karguth, Nina
Otify, Dina Yehia
Böhm, Sybille
Weber, Valentin Johannes
Bartoschek, Michael David
Splith, Victoria
Brümmer, Manuela
Ferreira, Raphael
Boon, Nanda
Wögenstein, Gabriele Maria
Grimm, Christian
Wijnholds, Jan
Mehlfeld, Verena
Michalakis, Stylianos
Fenske, Stefanie
Biel, Martin
Becirovic, Elvir
author_sort Riedmayr, Lisa Maria
collection PubMed
description Large genes including several CRISPR-Cas modules like gene activators (CRISPRa) require dual adeno-associated viral (AAV) vectors for an efficient in vivo delivery and expression. Current dual AAV vector approaches have important limitations, e.g., low reconstitution efficiency, production of alien proteins, or low flexibility in split site selection. Here, we present a dual AAV vector technology based on reconstitution via mRNA trans-splicing (REVeRT). REVeRT is flexible in split site selection and can efficiently reconstitute different split genes in numerous in vitro models, in human organoids, and in vivo. Furthermore, REVeRT can functionally reconstitute a CRISPRa module targeting genes in various mouse tissues and organs in single or multiplexed approaches upon different routes of administration. Finally, REVeRT enabled the reconstitution of full-length ABCA4 after intravitreal injection in a mouse model of Stargardt disease. Due to its flexibility and efficiency REVeRT harbors great potential for basic research and clinical applications.
format Online
Article
Text
id pubmed-10584818
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-105848182023-10-20 mRNA trans-splicing dual AAV vectors for (epi)genome editing and gene therapy Riedmayr, Lisa Maria Hinrichsmeyer, Klara Sonnie Thalhammer, Stefan Bernhard Mittas, David Manuel Karguth, Nina Otify, Dina Yehia Böhm, Sybille Weber, Valentin Johannes Bartoschek, Michael David Splith, Victoria Brümmer, Manuela Ferreira, Raphael Boon, Nanda Wögenstein, Gabriele Maria Grimm, Christian Wijnholds, Jan Mehlfeld, Verena Michalakis, Stylianos Fenske, Stefanie Biel, Martin Becirovic, Elvir Nat Commun Article Large genes including several CRISPR-Cas modules like gene activators (CRISPRa) require dual adeno-associated viral (AAV) vectors for an efficient in vivo delivery and expression. Current dual AAV vector approaches have important limitations, e.g., low reconstitution efficiency, production of alien proteins, or low flexibility in split site selection. Here, we present a dual AAV vector technology based on reconstitution via mRNA trans-splicing (REVeRT). REVeRT is flexible in split site selection and can efficiently reconstitute different split genes in numerous in vitro models, in human organoids, and in vivo. Furthermore, REVeRT can functionally reconstitute a CRISPRa module targeting genes in various mouse tissues and organs in single or multiplexed approaches upon different routes of administration. Finally, REVeRT enabled the reconstitution of full-length ABCA4 after intravitreal injection in a mouse model of Stargardt disease. Due to its flexibility and efficiency REVeRT harbors great potential for basic research and clinical applications. Nature Publishing Group UK 2023-10-18 /pmc/articles/PMC10584818/ /pubmed/37852949 http://dx.doi.org/10.1038/s41467-023-42386-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Riedmayr, Lisa Maria
Hinrichsmeyer, Klara Sonnie
Thalhammer, Stefan Bernhard
Mittas, David Manuel
Karguth, Nina
Otify, Dina Yehia
Böhm, Sybille
Weber, Valentin Johannes
Bartoschek, Michael David
Splith, Victoria
Brümmer, Manuela
Ferreira, Raphael
Boon, Nanda
Wögenstein, Gabriele Maria
Grimm, Christian
Wijnholds, Jan
Mehlfeld, Verena
Michalakis, Stylianos
Fenske, Stefanie
Biel, Martin
Becirovic, Elvir
mRNA trans-splicing dual AAV vectors for (epi)genome editing and gene therapy
title mRNA trans-splicing dual AAV vectors for (epi)genome editing and gene therapy
title_full mRNA trans-splicing dual AAV vectors for (epi)genome editing and gene therapy
title_fullStr mRNA trans-splicing dual AAV vectors for (epi)genome editing and gene therapy
title_full_unstemmed mRNA trans-splicing dual AAV vectors for (epi)genome editing and gene therapy
title_short mRNA trans-splicing dual AAV vectors for (epi)genome editing and gene therapy
title_sort mrna trans-splicing dual aav vectors for (epi)genome editing and gene therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10584818/
https://www.ncbi.nlm.nih.gov/pubmed/37852949
http://dx.doi.org/10.1038/s41467-023-42386-0
work_keys_str_mv AT riedmayrlisamaria mrnatranssplicingdualaavvectorsforepigenomeeditingandgenetherapy
AT hinrichsmeyerklarasonnie mrnatranssplicingdualaavvectorsforepigenomeeditingandgenetherapy
AT thalhammerstefanbernhard mrnatranssplicingdualaavvectorsforepigenomeeditingandgenetherapy
AT mittasdavidmanuel mrnatranssplicingdualaavvectorsforepigenomeeditingandgenetherapy
AT karguthnina mrnatranssplicingdualaavvectorsforepigenomeeditingandgenetherapy
AT otifydinayehia mrnatranssplicingdualaavvectorsforepigenomeeditingandgenetherapy
AT bohmsybille mrnatranssplicingdualaavvectorsforepigenomeeditingandgenetherapy
AT webervalentinjohannes mrnatranssplicingdualaavvectorsforepigenomeeditingandgenetherapy
AT bartoschekmichaeldavid mrnatranssplicingdualaavvectorsforepigenomeeditingandgenetherapy
AT splithvictoria mrnatranssplicingdualaavvectorsforepigenomeeditingandgenetherapy
AT brummermanuela mrnatranssplicingdualaavvectorsforepigenomeeditingandgenetherapy
AT ferreiraraphael mrnatranssplicingdualaavvectorsforepigenomeeditingandgenetherapy
AT boonnanda mrnatranssplicingdualaavvectorsforepigenomeeditingandgenetherapy
AT wogensteingabrielemaria mrnatranssplicingdualaavvectorsforepigenomeeditingandgenetherapy
AT grimmchristian mrnatranssplicingdualaavvectorsforepigenomeeditingandgenetherapy
AT wijnholdsjan mrnatranssplicingdualaavvectorsforepigenomeeditingandgenetherapy
AT mehlfeldverena mrnatranssplicingdualaavvectorsforepigenomeeditingandgenetherapy
AT michalakisstylianos mrnatranssplicingdualaavvectorsforepigenomeeditingandgenetherapy
AT fenskestefanie mrnatranssplicingdualaavvectorsforepigenomeeditingandgenetherapy
AT bielmartin mrnatranssplicingdualaavvectorsforepigenomeeditingandgenetherapy
AT becirovicelvir mrnatranssplicingdualaavvectorsforepigenomeeditingandgenetherapy